Working… Menu
Trial record 1 of 1 for:    iso-mc-091
Previous Study | Return to List | Next Study

An Extended Feasibility Phase I/II Study of Methylenetetrahydrofolate (Arfolitixorin) and Pemetrexed Single Agent, Given as Neoadjuvant Treatment in Patients With Resectable Rectal Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01397305
Recruitment Status : Completed
First Posted : July 19, 2011
Last Update Posted : September 9, 2020
Information provided by (Responsible Party):
Isofol Medical AB

No Study Results Posted on for this Study
Recruitment Status : Completed
Actual Primary Completion Date : October 16, 2014
Actual Study Completion Date : October 16, 2014